Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
$0.88
+1.5%
$0.81
$0.66
$2.43
$102.02M0.862.66 million shs1.68 million shs
Curis, Inc. stock logo
CRIS
Curis
$1.83
-5.2%
$2.16
$1.02
$8.29
$19.15M3.684,718 shs701,671 shs
Cortexyme, Inc. stock logo
CRTX
Cortexyme
$1.78
+4.1%
$1.22
$1.78
$40.66
$53.67M1.4620,672 shs370,847 shs
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
$35.93
-0.9%
$33.30
$27.66
$121.06
$4.63B1.191.49 million shs1.95 million shs
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
$37.44
-1.8%
$32.69
$6.76
$46.98
$3.55B0.331.30 million shs687,816 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
-0.12%+8.26%+7.70%+3.74%-39.36%
Curis, Inc. stock logo
CRIS
Curis
+5.46%+4.89%-23.11%+64.96%-71.91%
Cortexyme, Inc. stock logo
CRTX
Cortexyme
+6.21%+6.87%+46.15%+69.31%+137.50%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
+1.29%+9.04%-2.58%+16.15%-55.25%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
+3.05%+7.84%+10.75%+36.14%+360.94%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
3.8077 of 5 stars
3.30.00.04.52.22.50.6
Curis, Inc. stock logo
CRIS
Curis
2.4797 of 5 stars
3.54.00.00.01.80.00.6
Cortexyme, Inc. stock logo
CRTX
Cortexyme
N/AN/AN/AN/AN/AN/AN/AN/A
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
1.8897 of 5 stars
3.61.00.00.02.61.70.0
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
3.7732 of 5 stars
2.61.00.04.42.43.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
2.67
Moderate Buy$4.68432.20% Upside
Curis, Inc. stock logo
CRIS
Curis
3.00
Buy$17.00828.96% Upside
Cortexyme, Inc. stock logo
CRTX
Cortexyme
0.00
N/AN/AN/A
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
3.10
Buy$136.50279.91% Upside
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
3.14
Buy$42.6713.96% Upside

Current Analyst Ratings Breakdown

Latest SRRK, CHRS, PCVX, CRIS, and CRTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/18/2025
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$50.00
6/3/2025
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/19/2025
Curis, Inc. stock logo
CRIS
Curis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$17.00
5/14/2025
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$50.00
4/29/2025
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
4/24/2025
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$1.50 ➝ $1.05
4/22/2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
$272.25M0.37$0.30 per share2.98($1.14) per share-0.77
Curis, Inc. stock logo
CRIS
Curis
$11.20M1.71N/AN/A($0.71) per share-2.58
Cortexyme, Inc. stock logo
CRTX
Cortexyme
N/AN/AN/AN/A$3.97 per shareN/A
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/A$26.52 per shareN/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
$33.19M107.11N/AN/A$3.94 per share9.50
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
$28.51M-$1.13N/AN/AN/A-66.30%N/A-26.51%8/6/2025 (Estimated)
Curis, Inc. stock logo
CRIS
Curis
-$43.39M-$6.23N/AN/AN/A-376.08%N/A-97.14%7/30/2025 (Estimated)
Cortexyme, Inc. stock logo
CRTX
Cortexyme
-$89.94M-$2.97N/AN/AN/AN/A-70.96%-63.53%N/A
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$463.93M-$3.99N/AN/AN/AN/A-17.12%-16.26%8/5/2025 (Estimated)
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$246.29M-$2.53N/AN/AN/AN/A-118.22%-82.01%8/6/2025 (Estimated)

Latest SRRK, CHRS, PCVX, CRIS, and CRTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Curis, Inc. stock logo
CRIS
Curis
-$1.99N/AN/AN/AN/AN/A
8/5/2025Q2 2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$1.12N/AN/AN/AN/AN/A
5/14/2025Q1 2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$1.02-$1.04-$0.02-$1.04N/AN/A
5/14/2025Q1 2025
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$0.63-$0.67-$0.04-$0.67N/AN/A
5/12/2025Q1 2025
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
-$0.31-$0.35-$0.04-$0.49$59.79 million$7.60 million
5/6/2025Q1 2025
Curis, Inc. stock logo
CRIS
Curis
-$1.14-$1.25-$0.11-$1.25$2.37 million$2.38 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
N/AN/AN/AN/AN/A
Curis, Inc. stock logo
CRIS
Curis
N/AN/AN/AN/AN/A
Cortexyme, Inc. stock logo
CRTX
Cortexyme
N/AN/AN/AN/AN/A
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/AN/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
N/A
1.22
1.20
Curis, Inc. stock logo
CRIS
Curis
N/A
1.23
1.23
Cortexyme, Inc. stock logo
CRTX
Cortexyme
N/A
9.92
9.92
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/A
17.70
17.70
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
0.16
10.25
10.25

Institutional Ownership

CompanyInstitutional Ownership
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
72.82%
Curis, Inc. stock logo
CRIS
Curis
29.97%
Cortexyme, Inc. stock logo
CRTX
Cortexyme
63.18%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
96.78%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
91.08%

Insider Ownership

CompanyInsider Ownership
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
8.08%
Curis, Inc. stock logo
CRIS
Curis
5.45%
Cortexyme, Inc. stock logo
CRTX
Cortexyme
27.90%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
3.10%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
13.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
330115.93 million106.57 millionOptionable
Curis, Inc. stock logo
CRIS
Curis
6010.46 million9.89 millionNo Data
Cortexyme, Inc. stock logo
CRTX
Cortexyme
5530.15 million21.74 millionNot Optionable
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
160129.00 million125.01 millionOptionable
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
14094.95 million82.32 millionOptionable

Recent News About These Companies

Scholar Rock: EMBRAZE Results Drive The Stock Higher

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Coherus Oncology stock logo

Coherus Oncology NASDAQ:CHRS

$0.88 +0.01 (+1.48%)
Closing price 04:00 PM Eastern
Extended Trading
$0.88 +0.00 (+0.34%)
As of 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Curis stock logo

Curis NASDAQ:CRIS

$1.83 -0.10 (-5.18%)
Closing price 04:00 PM Eastern
Extended Trading
$1.80 -0.04 (-1.91%)
As of 06:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Cortexyme stock logo

Cortexyme NASDAQ:CRTX

$1.78 +0.07 (+4.09%)
As of 07/10/2025

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Vaxcyte stock logo

Vaxcyte NASDAQ:PCVX

$35.93 -0.31 (-0.86%)
Closing price 04:00 PM Eastern
Extended Trading
$35.92 -0.01 (-0.03%)
As of 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Scholar Rock stock logo

Scholar Rock NASDAQ:SRRK

$37.44 -0.68 (-1.78%)
Closing price 04:00 PM Eastern
Extended Trading
$37.47 +0.03 (+0.07%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.